STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck Animal Health to Acquire Elanco’s Aqua Business
Rhea-AI Summary
Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
acquisition
-
News
Elanco Announces Sale of Aqua Business for $1.3 Billion
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) announced the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, reinforcing its focus on pet health and livestock sustainability. The transaction will enable Elanco to accelerate debt paydown by $1.05B to $1.1B, with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025. The aqua business generated an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
News
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Merck (MRK) announced its fourth-quarter and full-year sales for 2023, reflecting sustained growth across oncology and vaccines. The worldwide sales for the fourth quarter were $14.6 billion, showing a 6% increase from the fourth quarter of 2022. For the full year, the sales were $60.1 billion, an increase of 1% from 2022. KEYTRUDA sales grew by 19% to $25.0 billion, and GARDASIL/GARDASIL 9 sales grew by 29% to $8.9 billion. However, LAGEVRIO sales declined by 75% to $1.4 billion. Merck also obtained FDA priority review of biologics license applications for V116, an investigational pneumococcal conjugate vaccine, and Patritumab Deruxtecan. The company initiated more than 20 phase 3 study starts and augmented its pipeline through acquisitions and collaboration agreements. The full-year 2024 financial outlook anticipates worldwide sales to be between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
earnings
News
The Wall Street Journal Names Merck Among Top 10 Best-Managed Companies
Rhea-AI Summary
Our company, MRK, has been recognized for its strong performance and leadership, ranking No. 10 on The Wall Street Journal's list of the 250 best-managed publicly traded U.S. companies in 2023. The company advanced 78 places from the previous year, showcasing its strategic focus, innovation, and unwavering commitment to saving and improving lives. MRK also secured the No. 1 spot on Newsweek's 2024 list of America's Most Responsible Companies, highlighting its dedication to corporate citizenship and responsible operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
News
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
Rhea-AI Summary
Merck (MRK) announced positive results from the Phase 3 KEYNOTE-564 trial, demonstrating a 38% improvement in overall survival (OS) with KEYTRUDA compared to placebo in patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following surgery. The OS rate at 48 months was 91.2% for KEYTRUDA patients compared to 86.0% for placebo patients. The trial also met its primary endpoint of disease-free survival (DFS) by reducing the risk of disease recurrence or death by 32%. The safety profile of KEYTRUDA was consistent with previous studies, with treatment-related adverse events occurring in 79.1% of KEYTRUDA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Unexpected Inspiration for More Sustainable Drug Development at Merck
Rhea-AI Summary
Merck scientist François Lévesque shares the amazing story of how creativity and Green Chemistry made drug development more sustainable. The inspiration for a greener world can come from unexpected places, as seen in this surprising journey from the pet store to sustainable drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
News
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Rhea-AI Summary
Merck announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma. KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 31% versus observation after surgery. Median DFS was 29.0 months for KEYTRUDA and 14.0 months for observation. Overall survival (OS) did not reach statistical significance at this interim analysis. KEYTRUDA is a potential new adjuvant option for patients with resectable muscle-invasive bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News
Merck Announces Second-Quarter 2024 Dividend
Rhea-AI Summary
Merck (NYSE: MRK) has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024, with payment to be made on April 5, 2024. This announcement reflects the company's commitment to providing returns to its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
dividends
-
News
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
Rhea-AI Summary
Merck (MRK) will hold its Q4 and full-year 2023 sales and earnings conference call on Feb. 1, providing an overview of performance and outlook for 2024. The call will be accessible via live audio webcast and a replay will be available on the company's website. Institutional investors, analysts, journalists, and the general public can join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
earnings
News
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has been approved by the FDA in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, which showed a 41% reduction in the risk of disease progression or death compared to placebo plus CRT. This marks the third indication for KEYTRUDA in cervical cancer and the 39th indication for KEYTRUDA in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#23 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1298 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.